develop market life scienc
tool integr system analyz nucleic
acid creat develop market
life scienc tool integr system
street-high pt
view current cl king meet event calendar coverag univers calendar
like clockwork post excel quarter beat top
bottom line manag rais guidanc howev line
revenu beat ep actual impli step spend
track bit base case novaseq go expect
benchtop legaci product beat expect thesi
compani five year unobstruct growth
production-scal sequenc investor underappreci abil
scale sb chemistri think novaseq shore weak near
term reiter buy rate street-high price target
base case thesi platform compani via genom
sequenc data gener overal market backdrop grow doubl
digit clinic sequenc repres potenti growth acceler
case re-fleet hiseq novaseq four-year pace
novaseq order per year anoth instrument new-to-high
upsid case thesi order stock see signific upsid
current valuat novaseq instrument need stage
evalu perhap adopt outsourc hiseq
custom site find addit new-to-high throughput custom novaseq
track level new-to-high throughput custom
mind consist approach upsid scenario upsid case
impli roughli novaseq exist high throughput custom
thesi near term think realiti fall somewher
two scenario long-term opportun top platform
sequenc help maintain premium multipl view
develop macro trend facilit continu double-digit growth
sequenc market year includ clinic sequenc companion
diagnost approv addit reimburs clinic sequenc
popul sequenc project emerg consum applic think
driver continu develop
detail quarter
requir disclosur end report
novaseq impli placement track bit us estim
consum well us consum vs instrument
chicken-and-egg-typ question drive
novaseq howev think consum might drive instrument
earli order pattern suggest largest custom buy
time rather complet re-fleet
hiseq hiseq consum decreas sequenti
lot less estim told us believ
hiseq custom survey suggest consum wont necessarili fall
cliff rather decreas gradual lack sequenc
consum drop-off contributor increas
benchtop sequenc nextseq continu domin benchtop space
compani even note growth sequenc benchtop sequenc
repres roughli one-quart compani revenu dont see
anyth slow fact see non-invasive prenat
test nipt includ adopt averag risk research
small panel well miseq custom demand higher throughput
consum genom still fire post revenu growth
array note mostli consum compani believ
brca approv could indic fda progress
view consum also note acceler interest helix
wegen consum isnt yet meaning contributor see
develop industri vital long-term growth sequenc
report revenu vs
beat our/th street respect estim
non-gaap ep beat our/street expect
all-around guidanc expect revenu
growth adjust ep
rang ep rang
revenu growth adjust ep
ep previous
model increas respect revenu estim
also
rais adjust ep forecast
respect
iseq iseq saw placement bit
expect said current import contributor
revenu howev still follow close see iseq
chemistri like chemistri eventu replac two-
channel chemistri current use novaseq right platform
expect mostli qc run
valuat deriv price target use
price-to-earnings multipl revis ep estim although
trade premium stock diagnost space believ
three five year unobstruct growth multibillion-dollar
address market multipl high end histor
trade rang howev visibl growth barrier entranc
never higher
page
risk achiev price target
increas competit space
inabl protect proprietari technolog
adopt speed novaseq
decreas govern spend
chang fda rule
page
